Alkermes (ALKS) Posts Q2 EPS of 1c, Tops by 10c; Guides FY09 Sales
More News related to ALKS
- Notable Analyst Rating Changes 11/17: XOM, PALM, ALKS, ITW, SINA Upgraded; SPWRA, PARD, PSUN, JOYG Downgraded
- Morning Movers 11/17: ZOOM, SMTL, AGO, ABCW, XJT Higher; INOC, QUIK, PSUN, ERI, FTK, TBUS Lower
- Alkermes Initiates Phase 2 Clinical Study of ALKS 33 for the Treatment of Alcohol Dependence
- Leerink Swann Upgrades Alkermes (ALKS) to Outperform; Significant Market Opportunity in Opioid Dependence
- Biotech Movers: SPEX, NABI, ALKS Up; PARD, CRXX Down
More News related to Earnings
- Keefe, Bruyette & Woods Downgrades First State Bancorporation (FSNM) to Market Perform
- Keefe, Bruyette & Woods Downgrades R&G Financial (RGFC) to Market Perform
Alkermes, Inc. (NASDAQ: ALKS) reports Q2 EPS of $0.01, veersus the analyst estimate of ($0.09). Revenue for the quarter was $48.2 million, which compares to the estimate of $45.85 million.
Sees FY10 sales $163 - $183 million
Related Categories
EarningsGuidance
Stocks Mentioned
-0.28Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
